F Pietrantonio Selected Research

F Pietrantonio Research Topics

Disease

16	Colorectal Neoplasms (Colorectal Cancer) 04/2024 - 10/2012
11	Neoplasms (Cancer) 04/2024 - 01/2014
2	Stomach Neoplasms (Stomach Cancer) 01/2021 - 12/2016
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2018 - 01/2014
2	Breast Neoplasms (Breast Cancer) 12/2018 - 12/2016
1	Constipation 10/2023
1	Diarrhea 10/2023
1	Exanthema (Rash) 10/2023
1	Hypothyroidism 10/2023
1	Nausea 10/2023
1	Rectal Neoplasms (Rectal Cancer) 10/2023
1	Neoplasm Metastasis (Metastasis) 12/2022
1	Esophageal Squamous Cell Carcinoma 01/2022
1	Neutropenia 12/2021
1	Febrile Neutropenia 12/2021
1	Microsatellite Instability 01/2021
1	Melanoma (Melanoma, Malignant) 12/2018
1	Obesity 01/2017
1	Thromboembolism 01/2017
1	Pseudomyxoma Peritonei 11/2016
1	Glioblastoma (Glioblastoma Multiforme) 09/2015
1	Carcinogenesis 01/2014

Drug/Important Bio-Agent (IBA)

4	Cetuximab (Erbitux)FDA Link 04/2024 - 10/2012
4	Irinotecan (Camptosar)FDA LinkGeneric 01/2023 - 07/2013
4	Bevacizumab (Avastin)FDA Link 12/2022 - 10/2012
3	ErbB Receptors (EGF Receptor)IBA 01/2023 - 12/2017
3	Oxaliplatin (Eloxatin)FDA LinkGeneric 12/2021 - 07/2013
3	Temozolomide (Temodar)FDA LinkGeneric 01/2018 - 02/2014
2	trifluridine tipiracil drug combinationIBA 04/2024 - 01/2017
2	regorafenibIBA 04/2024 - 01/2017
2	Leucovorin (Folinic Acid)FDA Link 12/2021 - 07/2013
1	encorafenibIBA 04/2024
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 04/2024
1	Capecitabine (Xeloda)FDA Link 10/2023
1	durvalumabIBA 10/2023
1	Transaminases (Aminotransferases)IBA 10/2023
1	Lipase (Acid Lipase)FDA Link 10/2023
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2023
1	Circulating Tumor DNAIBA 01/2023
1	avelumabIBA 01/2023
1	Fluorouracil (Carac)FDA LinkGeneric 12/2021
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 12/2021
1	Estrogens (Estrogen)FDA Link 12/2018
1	Indicators and Reagents (Reagents)IBA 12/2018
1	Immune Checkpoint InhibitorsIBA 12/2018
1	MethyltransferasesIBA 01/2018
1	Monoclonal AntibodiesIBA 12/2017
1	Plasminogen Activators (Plasminogen Activator)IBA 01/2017
1	Prothrombin (Factor II)IBA 01/2017
1	Plasminogen Activator Inhibitor 1IBA 01/2017
1	Factor V (Coagulation Factor V)IBA 01/2017
1	Methylenetetrahydrofolate Reductase (NADPH2) (Methylenetetrahydrofolate Reductase)IBA 01/2017
1	Trastuzumab (Herceptin)FDA Link 12/2016
1	Codon (Codons)IBA 10/2015
1	Calcibiotic Root Canal SealerIBA 10/2015
1	Alkylating AgentsIBA 09/2015
1	Dacarbazine (DIC)FDA LinkGeneric 09/2015
1	Cell-Free Nucleic AcidsIBA 09/2015
1	TegafurIBA 06/2014
1	UracilIBA 06/2014
1	MicroRNAs (MicroRNA)IBA 01/2014
1	Biomarkers (Surrogate Marker)IBA 07/2013

Therapy/Procedure

8	Therapeutics 04/2024 - 01/2014
8	Drug Therapy (Chemotherapy) 04/2024 - 07/2013
3	Immunotherapy 01/2022 - 12/2018
1	Neoadjuvant Therapy 10/2023
1	Chemoradiotherapy 10/2023
1	Continuity of Patient Care 06/2023
1	Combination Drug Therapy (Combination Chemotherapy) 10/2021
1	Radiotherapy 12/2018
1	Salvage Therapy 01/2018
1	Duration of Therapy 01/2017
1	Hyperthermic Intraperitoneal Chemotherapy 11/2016
1	Cytoreduction Surgical Procedures 11/2016